Positive new pooled data on Cosentyx in plaque psoriasis

Results from a pooled analysis of four Phase III clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as Week 4 when compared to placebo in patients who reported problems at baseline.

The data from a pooled analysis highlight the importance of considering quality of life, in addition to skin clearance, as part of a psoriasis management plan.

The results were presented at the 15th Annual Maui Derm for Dermatologists 2019 meeting, says the drug’s maker Novartis (NOVN: VX), whose share dipped 1.35% to 84.46 Swiss francs as the market closed, despite the positive data.